US-based Subsense has raised $10m, bringing the brain-computer interface (BCI) developer’s total funding to $27m since it emerged from stealth in February 2025.
The company’s latest investment, which follows its emergence from stealth, comes from venture capital company Golden Falcon Capital. The proceeds will be used to accelerate Subsense’s R&D efforts around nanoparticle sensing, in vivo biosafety programmes, next-generation nanoparticle design, and hardware miniaturisation, the company stated.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Subsense is developing a bidirectional BCI platform designed to record and modulate brain activity without surgical implants. BCIs create a direct communication channel between the brain’s electrical signals and an external technology, helping translate thoughts into actions in robotic limbs, computers, and other digital devices.
Subsense’s platform combines engineered nanoparticles, administered nasally to cross the blood-brain barrier, with proprietary hardware and signal-processing software.
By combining these technology protocols, the company aims to achieve higher temporal and spatial resolution of brain reading and stimulation than current solutions while avoiding the risks and costs associated with surgically invasive electrodes or implanted brain chips. Research indicates that these aspects are among the key barriers towards the technology’s scalability.
Subsense’s co-founder and CEO Tetiana Aleksandrova commented: “We are developing a new kind of neural interface, which integrates seamlessly with the human body. This bio-integrated approach is fundamentally enhancing safety and expanding accessibility.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGrowth in the BCI space
The BCI space is continuing to evolve at pace and has demonstrated significant potential in areas such as the restoration of movement for amputees.
Morgan Stanley estimates that the BCI space has an early total addressable market (TAM) of $80bn across three million US adults. Potentially reaching $320bn with further advancements, patients with conditions such as multiple sclerosis and spinal cord injuries represent a significant portion of the market.
Neuralink currently appears to be the leading player on the BCI scene. Led by entrepreneur Elon Musk, the company has several clinical trials underway that are evaluating its implantable brain chip in a range of indications.
For example, Neuralink’s CAN-PRIME (NCT06700304) trial is evaluating the feasibility of its N1 Implant and R1 Robot in restoring movement in people who have difficulty moving their arms and legs.
Neuralink completed a $650m Series E financing round in June. While other BCI companies are further along in their clinical journeys, Neuralink’s significant capital puts it at an advantage. According to internal documents seen by Bloomberg in August, the company appears to be the closest to commercialising its technology.
The documents revealed that Neuralink plans to have five large clinics in operation by 2031, with three versions of its BCI chip available. Neuralink expects Telepathy – the company’s BCI for limbic control through “thoughts alone” – to be approved by the US Food and Drug Administration (FDA) by 2029.
While it appears that Neuralink is currently leading the way in the BCI space, Scott Meek, head of R&D at Subsense, previously told Medical Device Network that leadership in the space remains “far from settled”.
Meek pointed out that the space’s current dynamics could “quickly shift” as other well-capitalised players enter the space.
